1. Taiwan, Province of China Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Welgene Biotech Co.,Ltd.

Welgene Biotech Co.,Ltd.

6661.TWO
Welgene Biotech Co.,Ltd.TW flagTaipei Exchange
18.25
TWD
+0.45
- -
425.30MMarket Cap
Welgene Biotech Co.,Ltd.
6661.TWO
(Taipei Exchange)

Recent

price

18.25

P/E

ratio

- -

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
24.66
17.33
13.44
15.73
18.57
20.16
19.23
13.54
13.81
12.04
13.84
- -
16.24
Revenue per Share
1.93
1.33
0.2
1.14
1.37
1.49
1.44
0.59
0.41
-0.11
0.05
- -
0.06
Basic EPS, GAAP
0.15
-0.96
0.12
1.14
1.91
3.7
1.73
0.3
1.05
-1.21
2.2
- -
-0.26
Free Cash Flow per Basic Share
2.13
- -
- -
0.18
0.29
1.26
1.34
1.11
0.48
0.18
- -
- -
- -
Dividend per Share
6.9
12.08
9.46
10.4
11.4
11.49
11.48
10.69
10.41
9.85
9.9
- -
10
Book Value per Share
10.43
12.4
9.73
10.71
11.84
12.02
12.14
13.38
13.01
12.87
12.68
- -
12.33
Tangible Book Value per Share
11
16
21
21
21
21
21
23
23
23
23
- -
23
Basic Weighted Avg Shares
270
277
278
326
384
417
398
313
322
281
323
376
376
Sales/Revenue/Turnover
-7.59
4.76
5.08
9.01
10.15
9.4
9.16
4.7
4.93
-1.73
-0.22
0.02
0.02
Operating Margin (%)
5
7
7
8
8
8
18
19
19
27
29
28
28
Depreciation Expense
21
21
4
24
28
31
30
14
10
-3
1
1
1
Net Income, GAAP
8.1
8.89
48.51
18.3
23.63
22.52
19.82
17.43
29.58
- -
43.52
3.14
3.14
Effective Tax Rate (%)
7.81
7.68
1.47
7.26
7.37
7.39
7.48
4.38
2.97
-0.94
0.34
0.35
0.35
Profit Margin (%)
87
169
175
184
191
172
169
227
197
178
187
199
199
Working Capital
9
6
4
2
- -
22
11
- -
27
119
96
171
171
LT Debt
114
200
204
224
247
251
253
310
304
300
296
286
286
Total Equity
- -
5.99
3.09
9.57
11.2
10.73
9.99
3.92
3.23
- -
-0.09
0.01
0.01
Return on Invested Capital (%)
- -
12.62
1.98
10.1
11.46
11.68
11.02
5.22
3.46
- -
0.84
1.12
1.12
Return on Capital (%)
- -
15.83
2.1
11.5
12.56
13.03
12.52
5.66
3.9
-1.12
0.48
0.58
0.58
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
ST Debt
38
39
55
LT Borrowings
112
127
141
LT Finance Leases
- -
- -
30
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
23
23
23
Market Capitalization
478
516
431

Working Capital

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
Total Current Assets
335
349
364
Cash, Cash Equivalents & STI
236
255
269
Accounts Receivable, Net
47
46
45
Inventories
43
38
39
Total Current Liabilities
133
133
164
Payables & Accruals
- -
- -
- -
ST Debt
38
39
55
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.92%
2.94%
-3.27%
Free Cash Flow
38.88%
-86.65%
-113.21%
Net Income, GAAP
8.85%
-66.73%
20.14%
Sales/Revenue/Turnover
3.95%
0.03%
16.55%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
49
77
80
74
281
2024
68
76
90
88
323
2025
78
90
110
98
376

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
-0.21
0.25
-0.04
- -
-0.11
2024
-0.24
-0.02
0.33
- -
0.05
2025
-0.2
-0.02
0.3
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.18
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Medivolve Inc. (4NC.F)
SeqLL Inc. (SQLLW)
Trinity Biotech plc (TRIB)
China Biotech Services Holdings Limited (8037.HK)
Diaceutics PLC (DXRX.L)
Standard BioTools Inc. (FLDM)
Business
Welgene Biotech Co., Ltd. (6661.TWO) provides genetic testing services and biotechnology products in Taiwan. The company offers research services including next-generation sequencing (NGS), DNA microarray analysis, real-time quantitative PCR (qPCR) verification, nucleic acid extraction, proteomics analysis, bioinformatics services, and third-generation PacBio sequencing; it also trades medical equipment and genetic testing reagents as the exclusive distributor for Agilent Technologies' Genomics product line in Taiwan, alongside products from Guardant, Somalogic, Epigenetek, and Ops Diagnostics. Welgene Biotech serves academic research units, hospitals, biotechnology companies, and clinical applications such as prenatal genetic screening developed in partnership with Changhua Christian Hospital. Founded in 2003 and headquartered at 12F, No. 3, Yuanyuan Street, Nangang District, Taipei City, Taiwan, the company operates primarily in the domestic Taiwanese market with ISO 17025-accredited laboratories focused on high-throughput genomic technologies.